Navigation Links
Centrix Pharmaceutical Announces Clofera(TM), a Unique Antitussive and Nasal Decongestant for the Temporary Relief of Cough and Nasal Congestion
Date:8/14/2009

BIRMINGHAM, Ala., Aug. 14 /PRNewswire/ -- Centrix Pharmaceutical, Inc., a privately-held specialty pharmaceutical company focused on Pediatrics and Women's Health, announced plans to commercially launch Clofera(TM) for the temporary relief of cough and nasal congestion.

Clofera(TM) is indicated for the temporary relief of cough and nasal congestion due to the common cold, hay fever, or other upper respiratory allergies. Clofera(TM) contains a non-narcotic antitussive, chlophedianol hydrochloride, in addition to nasal decongestant, pseudoephedrine hydrochloride. The product is specifically formulated without dyes, sugar, alcohol or gluten to meet particular consumer needs and address patient sensitivities. Clofera(TM) is expected to release during the beginning of the fourth quarter.

"We are pleased to introduce Clofera to temporarily control the cough reflex, therefore reducing the intensity of coughing with a product that is free of narcotic effects. Clofera provides physicians with another therapeutic option in the management of cough and congestion associated with allergic rhinitis or the common cold. The release of Clofera further compliments our goal to develop and expand the Centrix specialty portfolio," stated John R. (Bob) Booth, President and CEO of Centrix Pharmaceutical.

About Clofera(TM)

Clofera(TM) temporarily controls the cough reflex, temporarily relieves nasal congestion, swollen nasal passages, sinus congestion and pressure. Clofera(TM) should not be used in patients taking monoamine oxidase inhibitors or with known hypersensitivity to any of the components of the product. Patients with a chronic cough, asthma, emphysema, mucus production, heart disease, high blood pressure, thyroid disease, diabetes, or enlarged prostate should consult physician before use. Recommended dosage should not be exceeded. Clofera(TM) contains no dextromethorphan, antihistamines, sugar, alcohol, or dyes and is gluten free. Clofera(TM) will be available in grape flavor.

About Centrix Pharmaceutical, Inc.

Centrix Pharmaceutical is a privately-held specialty pharmaceutical company focused in Pediatrics and Women's Health. Headquartered in Birmingham, AL, the Company's products are marketed by its dedicated sales force in the United States. For more information about Centrix Pharmaceutical, Inc. visit www.cenrx.com.


'/>"/>
SOURCE Centrix Pharmaceutical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. CareCentrix Adds to Senior Leadership Team
2. HeartCentrix Informatics Solution from Cardiac Science Now Certified with Allscripts Electronic Health Records
3. Gentiva(R) Health Services Promotes Boelsen to Senior Vice President, CareCentrix(R)
4. Cardiac Science Announces HeartCentrix(R) ECG Informatics Connectivity With Henry Schein Medical Systems MicroMD(R) EMR 5.0
5. Cardiac Science Announces HeartCentrix(R) ECG Informatics Connectivity With Greenway(R) Medical Technologies
6. WuXi PharmaTech Selected as One of the Top Ten Employer for New College Graduates in Pharmaceutical Industry in 2009
7. Hisamitsu Pharmaceutical Announces Expiration of HSR Waiting Period for Its Proposed Acquisition of Noven Pharmaceuticals
8. Mylan Pharmaceuticals Receives Final FDA Report and Reaffirms Its 48-Year Exemplary Record of Quality
9. Thomson Reuters Invites You to the First Latin American Forum Covering the Pharmaceutical Industry
10. Sun Pharmaceutical to File HSR Application for Taro Tender Offer
11. Endo Pharmaceuticals Announces Resignation of Chief Operating Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... May 27, 2016 , ... Two director-level employees of ... Tribute to Women and Industry (TWIN) 2016 honorees. The award recognizes businesswomen who ... this year, Geri Boone, Director of the MLTSS (Managed Long-Term Services and Supports) Program ...
(Date:5/27/2016)... ... 27, 2016 , ... With over 60 percent of acute stroke survivors being ... product to aid in the rehabilitation process has steadily increased. Ekso Bionics had been ... hemiplegia due to stroke. , Ekso Bionics has now received clearance from the U.S. ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... help educate the many who are unaware of the plight of aphasia. In ... run within the “Stroke Awareness” campaign. , The link between stroke and aphasia ...
(Date:5/27/2016)... ... , ... Aimed at nurses and employees in the health care world, this ... the nursing and health care industry. It also provides insight to the developing trends ... , As the nursing industry is coming out of one of the biggest recessions ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... Despite last ... meeting, expect Janet Yellen and company to wait until March 2017 for an interest ... University’s J. Mack Robinson College of Business. , “The Federal Open Market Committee (FOMC) ...
Breaking Medicine News(10 mins):
(Date:5/30/2016)... 30, 2016 LifeScienceIndustryResearch.com adds ... research report with comprehensive information on the therapeutic ... at various stages, therapeutics assessment by drug target, ... and molecule type, along with latest updates, and ... key players involved in the therapeutic development for ...
(Date:5/27/2016)... LONDON , May 27, 2016 ... an innovative biopharma company focused on the highly ... built a substantial pipeline of potential first-in-class or ... which are in development with strategic partners. HCM,s ... the fast-growing domestic market. We expect progress of ...
(Date:5/26/2016)... -- A key trend that will boost ... new treatments. Cardax, a development stage life sciences company, ... is expected to fulfil large unmet medical needs in ... to develop new treatments for osteoarthritis. One such study ... osteoarthritis are being investigated, and early trials of stem-cell ...
Breaking Medicine Technology: